language_icon
EN
HI

Syngene International Share price

SYNGENE

458.1

9.25 (-1.98%)
NSE
BSE
Last updated on 8 May, 2026 | 15:58 IST
Today's High

469.90

Today's Low

456.15

52 Week Low

380.00

52 Week High

728.60

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Syngene International Chart

Syngene International Share Key Metrics

Volume
6.50 L
Market Cap
18458.65 CR
LTQ@LTP
1@458.10
ATP
462.76
Var Margin
16.91 %
Circuit Range
373.9-560.8
Delivery %
29.54 %
Value
30.09 CR
ASM/GSM
No
Market Lot
1

Summary

Syngene International share price stands at ₹458.1 at 8 May, 2026 | 15:58. The stock Syngene International intraday movement has stayed between ₹456.15 and ₹469.90, while on a 52-week basis it has fluctuated from ₹380.00 to ₹728.60.
In terms of trading activity, Syngene International has recorded a volume of 650201 shares. The Syngene International has a market cap of ₹402939420. The stock’s Average Traded Price (ATP) stands at ₹46276, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 1, 45810.
The Syngene International operates within a circuit range of ₹373.9-560.8 – ₹373.9-560.8, with a Value of ₹30.09 CR. The Delivery Percentage for the day is 29.54%. Additionally, Syngene International currently falls under the No framework, and trades with a market lot size of 1.

Syngene International Fundamentals

View More
P/E Ratio

58.38

P/B Ratio

3.82

Div. Yield

0.27

Sector P/E

26.28

Sector P/B

2.73

Sec. Div. Yield

1.03

Syngene International Resistance and Support

Pivot 464.83

Resistance

First Resistance

479.51

Second Resistance

491.68

Third Resistance

506.36

Support

First Support

452.66

Second Support

437.98

Third Support

425.81

Syngene International Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

52.68%

Mutual Fund

24.18%

Insurance

2.14%

Foreign Institutional Investors

13.91%

Domestic Institutional Investors

0.12%

Retail

6.98%

Others

-0.01%

Total Promoters
MAR '26
52.68%

Syngene International Corporate Actions

DateAgenda
2026-04-29Audited Results & Final Dividend
2026-01-22Quarterly Results
2025-11-05Quarterly Results
2025-07-23Quarterly Results
2025-04-23Audited Results & Final Dividend
2025-01-23Quarterly Results

Syngene International News

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Syngene International has made the transcript of its Q4 FY2026 Earnings Call available. The call was held on April 30, 2026, providing investors access to detailed discussions.
May 04 2026 21:05:00

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Syngene International has made available the audio recording of its Q4 FY26 post-earnings call. The recording was uploaded on the company's website on April 30, 2026, for investor access.
Apr 30 2026 17:04:00

Syngene International Ltd - 539268 - Syngene International Limited Has Informed The Exchange That Record Date For The Purpose Of Dividend Is June 26, 2026.

Syngene International has set June 26, 2026, as the record date for a final dividend of ₹1.25 per share for FY26. Payment will be made within 30 days of shareholders' approval.
Apr 29 2026 22:04:00

Syngene International Limited

Syngene International appointed Mr. Siddharth Mittal as its new Managing Director & CEO, effective July 1, 2026. This follows the resignation of current MD & CEO, Mr. Peter Bains, effective June 30, 2026, ensuring a smooth leadership transition.
Apr 29 2026 19:04:00

Syngene International Ltd - 539268 - Intimation Of Change In Key Managerial Personnel (KMP) To Determine Materiality Of An Event Or Information

Syngene International has appointed Siddharth Mittal as its new Managing Director & CEO. This leadership transition will be effective from July 01, 2026, with Mr. Mittal taking over from Peter Bains.
Apr 29 2026 19:04:00

Syngene International Ltd - 539268 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Syngene International reported Q4 FY26 net profit of Rs.153 cr, a 16% YoY decline, while full-year net profit for FY26 dropped 20% to Rs.380 cr on revenue of Rs.3,739 cr, up 3% YoY. The company also announced leadership changes and a Rs.1.25 dividend.
Apr 29 2026 18:04:00

Syngene International Ltd - 539268 - Board Meeting Outcome for Syngene International Limited Has Submitted To The Exchange, The Financial Results For The Period Ended March 31, 2026.

Syngene International's board approved Q4 FY26 cons. revenue of ₹10.37 bn (up 1.8% YoY) and net profit of ₹1.48 bn (down 19.3% YoY). The board also recommended a final dividend of ₹1.25 per equity share for FY26, with June 26, 2026, as the record date.
Apr 29 2026 18:04:00

Syngene International Limited

Syngene International filed its shareholding pattern for Q4 FY26. Promoters held 52.68% of the company's shares, while public shareholders held 47.03%. Significant institutional holdings included Mutual Funds at 24.18% and FPIs at 13.91%.
Apr 17 2026 19:04:00

Syngene International Limited

Syngene International board will meet on April 29, 2026, to consider and approve its audited annual financial results for FY26. The meeting will also include a recommendation for a final dividend.
Apr 15 2026 17:04:00

Syngene International Ltd - 539268 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Nippon Life India Asset Management Ltd acquired 1,600,307 shares of Syngene International Limited via open market. This transaction, executed between February 16, 2026 and April 10, 2026, increased its stake to 7.1168% from 6.7197% on behalf of Nippon India Mutual Fund.
Apr 15 2026 17:04:00
Read More

About Syngene International

NSE : 10243  
BSE : 539268  
ISIN : INE398R01022  

The Company was incorporated as Syngene International Private Limited on November 18 1993 at Bengaluru Karnataka as a private limited company under the Companies Act 1956. Pursuant to a special resolution of the shareholders dated March 26 2007 the Company was converted into a public limited company and the name of the Company was changed to Syngene International Limited. A fresh certificate of incorporation consequent upon conversion to public limited company was issued on April 19 2007. the Company was promoted by Kiran Mazumdar Shaw a promoter of Biocon. On March 30 2002 99.9 percent of the Equity Shares of the Company were transferred to Biocon and as a result the Company became the subsidiary of Biocon. Biocon has since been the Promoter of the Company.The details of changes in the registered office of the Company are given below: From 20th KM Hosur Road Electronics City P.O Bengaluru 560 100 Karnataka India to Biocon Special Economic Zone Biocon Park Plot No. 2 and 3 Bommasandra Industrial Area IV Phase Jigani Link Road Bommasandra Bengaluru 560 099 Karnataka India.Major events and milestones of the Company :1994 -Initiated operations as a CRO with services in chemistry and biology1998 -Granted 100% Export Oriented Unit (EOU) status by the Government of India 1999 -First operational expansion in R&D by way of expansion of lab space to over 23000 sq. ft. 2000 -CIL was incorporated as a 100% subsidiary of Biocon to provide clinical research services to domestic and multinational companies 2001 -Forayed into chemical development with a dedicated manufacturing facility 2003 -Moved to Biocon Park a 90 acre biopharmaceutical SEZ with operations spread over 65000 sq. ft. 2007-Bristol-Myers Squibb and the Company signed the first long term contract to set up the first dedicated R&D centre -Expansion of research facilities at Biocon SEZ to 148000 sq. ft. -Crossed an annual turnover of over `1000 million in Financial Year 2007 2009-Dupont Crop Protection and the Company extended a partnership for R&D services -Expansion of manufacturing services with a new plant which is cGMP compliant -Initiated operations in safety assessment and large molecules development services 2010-Acceptance of the clinical and bio-analytical facilities of CIL by the Department of Health & Human Services FDA -Initiated operations in formulation development 2011-Endo Pharmaceuticals and the Company collaborated to develop novel biological therapeutic molecules against cancer 2012-Abbott and the Company collaborated to establish Abbott's nutrition research and development centre in India and the second R&D centre -Certification of the clinical facilities by ANVISA -Acquired 100% stake in Clinigene International Limited from Biocon 2013 -Crossed an annual turnover of over `5000 million in Financial Year 2013 -Baxter International Inc. collaborated with the Company to establish the ?Baxter Global Research Center? the third dedicated R&D centre -Acceptance of the control testing laboratory by the Department of Health & Human Services FDA 2014-Bristol-Myers Squibb and the Company extend collaboration for its dedicated R&D centre till 2020 -Acceptance of the API manufacturing facility by the Department of Health & Human Services FDA -Established a 75000 sq.ft centre to provide stability and analytical services 2015-CIL was amalgamated with the Company Awards Recognitions and Accreditations :2009- Bangalore Bio Bio Excellence Award ? Biotech Services Sector - Best BioServices company of the year by Biospectrum 2012- ISO 9001:2008 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - AAALAC accreditation for conforming to the ?Guide for the Care and Use of Laboratory Animals and the Committee for the Purpose of Control and Supervision of Experiments on Animals guidelines? 2013- Bioservices - ABLE Tenth Anniversary Award ? Outstanding contribution to Bioservices - Diamond sponsor recognition by the Association of Scientists of Indian Origin of the Society of Toxicology 2014- ISO 14001:2004 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - BS OHSAS 18001:2007 for contract research in drug discovery and contract manufacturing of biopharmaceuticals - Silver EDGE Award - EHS best practices award by CII - SAP Ace Award for special recognition for complex SAP implementation - Level I Laboratory certification issued by the NGSP to Clinigene International Limited 2015- Accreditation by the College of American Pathologists in relation to their laboratory accreditation program - Bangalore India Bio ? Bio Excellence Award for outstanding contribution to the Biotech services sector - ISO 15189:2007 in the field of medical testing

Read More

Syngene International Management

NamePosition
Kiran Mazumdar-ShawChairperson
Peter BainsManaging Director & Chief Executive Officer
View More

Syngene International FAQs

The Buying Price of Syngene International share is 458.1 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Syngene International stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Syngene International, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Syngene International shares is 58.38. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Syngene International shares is 3.82. Useful to assess the stock's value relative to its book value.

To assess Syngene International’s valuation compare Sector P/E, P/B which are 26.28 & 2.73 with sector averages, along with growth rates and financial metrics.

The Market Cap of Syngene International is 18458.65 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Syngene International share price is 728.60 & 380.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Syngene International belongs to the Miscellaneous sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost